T cells have the capacity to eradicate diseased cells, but tumours present considerable challenges that render T cells ineffectual. Cancer cells often make themselves almost 'invisible' to the immune system, and they sculpt a microenvironment that suppresses T cell activity, survival and migration. Ge...
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood 105, 3087–3093 (2005). Article CAS PubMed Google Scholar Brocker, T. Chimeric Fv-ζ or Fv-ε receptors are not sufficient to induce activation or cytokine production in ...
Cytotoxic T cells are CD8-postive T cells that are specialized for the direct killing of cells that are infected (particularly with viruses), cancerous or damaged in other ways. They express the glycoprotein CD8, as well as T cell receptors that recognize antigenic peptides presented by MHC cl...
CARs, T cells that express CARs or tumor-specific T cell receptors (TCRs), and the interaction between engineered T cells and the tumor microenvironment (TME), with particular focus on improving the efficacy and safety of adoptive T cell therapy for the treatment of solid tumors (Figure 1)....
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy 2022, Seminars in Cancer Biology Citation Excerpt : Different from PD-L1, PD-1 mainly expresses on activated T and B cells [7]. Although the regulation of PD-1 on transcriptional levels has...
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer ...
Adoptive cell therapy using patient-derived chimeric receptor antigen (CAR) T cells redirected against tumor cells has shown remarkable success in treating hematologic cancers. However, wider accessibility of cellular therapies for all patients is needed
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the trea
Type I IFN substitutes for T cell help during viral infections. J. Immunol. 186, 754–763 (2011). Article CAS PubMed Google Scholar Schulz, O. et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 13, 453–...